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Obtained results clearly show that it is necessary to improve health and
drug policies in order to improve the possibility of effective treatment of
these patients in accordance with the recommendations and clinical
guidelines.
Antipsychotics are drugs mainly used in therapy of symptoms of psychosis such as schizophrenia, manic psychosis, depression etc. The
treatment of the patients with psychotic conditions is directly connected with physical and financial availability of safe, effective and drugs
with good quality. The analysis of the market of antipsychotics implies analysis of all antipsychotics registered in Republic of Macedonia,
their status as regards the reimbursement, financial and physical availability, compared with the recommendations for the treatment of these
diseases in evidence-based medicine and other therapeutic guides, as well as the analysis of the consumption of antipsychotic products
dispensed and reimbursed by the Health Insurance Fund (HIF) in pharmacies in Macedonia.
For this purpose, we used relevant data from primary,
secondary and tertiary literature, recommendations from
Evidence-based Medicine, official data from world and
national drug registers and published reports from the HIF
of Republic of Macedonia for consumption of
antipsychotics from the Positive List for the period 2011-
2015. For data processing we used the descriptive method
and presented the obtained results in tabular form.
RESULTS AND DISCUSSION
-The market of antipsychotics in Republic of Macedonia is characterized
with high presence of generic drugs, high consumption determined by
the number of issued prescriptions and also by the financial amount.
Innovative drugs hardly enter the market and even more difficult on the
Positive List, due to the financial constraint of the Health Insurance
Fund and complicated procedures. These important factors significantly
limit the possibility of doctors’ choice to introduce new therapy in these
patients, to monitor the effects of treatments and also to gain experience
with innovative drugs and treatment.
Table 1. Market analysis of antipsychotics determined by number 
of issued prescriptions in 2015
Table 2. Consumption growth of antipsychotics in period 2011-
2015
Disease
Therapies
according to EBM
Registered antipsychotics
in the world
Registered antipsychotics
in R.Macedonia
Antipsychotics in
R.Macedonia reimbursed
by HIF
Acute psychosis
Risperidone
Quetiapine
Aripiprazole
Olanzapine
Ziprasidone
Risperidone
Quetiapine
Aripiprazole
Olanzapine
Ziprasidone
Risperidone
Quetiapine
Aripiprazole
Olanzapine
Risperidone
Olanzapine
Bipolar disorder Olanzapine Olanzapine Olanzapine Olanzapine
Delusional disorder Risperidone Risperidone Risperidone Risperidone
Psychosis in elderly
patients
Risperidone
Quetiapine
Olanzapine
Haloperidol
Aripiprazole
Ziprasidone
Risperidone
Quetiapine
Olanzapine
Haloperidol
Aripiprazole
Ziprasidone
Risperidone
Quetiapine
Olanzapine
Haloperidol
Aripiprazole
Risperidone
Olanzapine
Haloperidol
Treatment of dementia Risperidone
Quetiapine
Risperidone
Quetiapine
Risperidone
Quetiapine
Risperidone
Schizophrenia
Chlorpromazine
Perphenazine
Risperidone
Olanzapine
Chlorpromazine
Perphenazine
Risperidone
Olanzapine
Risperidone
Olanzapine
Chlorpromazine
Risperidone
Olanzapine
Table 3. Antipsychotics indicated for treatment of various diseases 
according to EBM
